These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 35821026)

  • 1. The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS.
    Ha H; Kang JH; Kim DY; Bae SJ; Lee HY
    BMC Health Serv Res; 2022 Jul; 22(1):900. PubMed ID: 35821026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
    Everest L; Shah M; Chan KKW
    JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
    McGregor B; Geynisman DM; Burotto M; Porta C; Suarez C; Bourlon MT; Del Tejo V; Du EX; Yang X; Sendhil SR; Betts KA; Huo S
    Oncologist; 2023 Jan; 28(1):72-79. PubMed ID: 36124890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
    McGregor B; Geynisman DM; Burotto M; Suárez C; Bourlon MT; Barata PC; Gulati S; Huo S; Ejzykowicz F; Blum SI; Del Tejo V; Hamilton M; May JR; Du EX; Wu A; Kral P; Ivanescu C; Chin A; Betts KA; Lee CH; Choueiri TK; Cella D; Porta C
    Eur Urol Oncol; 2023 Jun; 6(3):339-348. PubMed ID: 36842942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real world treatment sequences and outcomes for metastatic renal cell carcinoma.
    Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Lin CY; Hung SC; Chiu KY; Yang SF
    PLoS One; 2023; 18(11):e0294039. PubMed ID: 37992086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape.
    Gulati S; Labaki C; Karachaliou GS; Choueiri TK; Zhang T
    Oncologist; 2022 Mar; 27(2):125-134. PubMed ID: 35641205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies.
    Li S; Li J; Peng L; Li Y; Wan X
    Front Pharmacol; 2021; 12():718014. PubMed ID: 34566643
    [No Abstract]   [Full Text] [Related]  

  • 11. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
    Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
    J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data.
    Tomida R; Takahashi M; Matsushita Y; Kojima T; Yamana K; Kandori S; Bando Y; Nishiyama N; Yamashita S; Taniguchi H; Monji K; Ishiyama R; Tatarano S; Masui K; Matsuda A; Kaneko T; Motoshima T; Shiraishi Y; Kira S; Murashima T; Hara H; Matsumura M; Kitamura H; Miyake H; Furukawa J;
    Clin Genitourin Cancer; 2024 Jun; 22(3):102094. PubMed ID: 38714434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis.
    Fujiwara Y; Miyashita H; Liaw BC
    Cancer Immunol Immunother; 2023 Jun; 72(6):1355-1364. PubMed ID: 36495342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma.
    Shay R; Nicklawsky A; Gao D; Lam ET
    Clin Genitourin Cancer; 2021 Aug; 19(4):370-370.e7. PubMed ID: 33674224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.
    Cao G; Wu X; Wang Z; Tian X; Zhang C; Wu X; Zhang H; Jing G; Yan T
    BMJ Open; 2020 Aug; 10(8):e034626. PubMed ID: 32859659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis.
    Chen X; Xu Z; Wu C; Xie L; Wang P; Liu X
    Front Immunol; 2024; 15():1255577. PubMed ID: 38390328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma.
    Mason NT; Joshi VB; Adashek JJ; Kim Y; Shah SS; Schneider AM; Chadha J; Jim HSL; Byrne MM; Gilbert SM; Manley BJ; Spiess PE; Chahoud J
    Eur Urol Oncol; 2023 Jun; 6(3):331-338. PubMed ID: 36797084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab.
    Niewada M; Macioch T; Konarska M; Mela A; Goszczyński A; Przekopińska B; Rajkiewicz K; Wysocki P; Krzakowski M
    Front Pharmacol; 2022; 13():1063178. PubMed ID: 36937206
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
    Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
    Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
    Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L
    Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.